Rami Manochakian/X
Jun 12, 2025, 19:07
Rami Manochakian: FDA Approves Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer Based on TRUST Trials
Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared on X:
“Hot Off The Press
U.S. FDA approves Taletrectinib for locally advanced or metastatic ROS1+ non-small cell Lung Cancer.
Approval based on TRUST I and II Trials.
– ORR:
85-90% for treatment-naive patients
52-62% or TKI-pretreated patients”
More posts featuring Rami Manochakian on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 13, 2025, 09:06
Jun 13, 2025, 08:53
Jun 13, 2025, 08:45